CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
IBI334drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05774873
NCT05774873Phase 2Completed
CompareCT.gov

A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.·interventional·Posted Mar 20, 2023·Updated Jan 6, 2026

In Brief

A Phase 2 clinical trial evaluating IBI334 for Advanced Solid Tumors. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedMar 20, 2023
Enrollment StartAug 9, 2023
Primary CompletionMar 20, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.3 years ago

Interventions

IBI334drug

There are six dose of IBI334 ,QW IV in first cycle and Q2W IV behind the first cycle